Becton Dickinson and Company (BDX)vsNephros Inc (NEPH)
BDX
Becton Dickinson and Company
$195.16
+0.07%
HEALTHCARE · Cap: $52.23B
NEPH
Nephros Inc
$3.17
-9.69%
HEALTHCARE · Cap: $38.34M
Smart Verdict
WallStSmart Research — data-driven comparison
Becton Dickinson and Company generates 108403% more annual revenue ($22.48B vs $20.72M). NEPH leads profitability with a 8.4% profit margin vs 4.2%. NEPH trades at a lower P/E of 23.5x. NEPH earns a higher WallStSmart Score of 59/100 (C).
BDX
Buy52
out of 100
Grade: C-
NEPH
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+10.7%
Fair Value
$202.19
Current Price
$195.16
$7.03 discount
Margin of Safety
+11.8%
Fair Value
$4.58
Current Price
$3.17
$1.41 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Reasonable price relative to book value
Revenue surging 36.2% year-over-year
Earnings expanding 450.0% YoY
Conservative balance sheet, low leverage
Reasonable price relative to book value
Strong operational efficiency at 20.2%
Areas to Watch
ROE of 3.9% — below average capital efficiency
4.2% margin — thin
Premium valuation, high expectations priced in
Earnings declined 31.4%
Smaller company, higher risk/reward
ROE of 7.3% — below average capital efficiency
Weak financial health signals
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : BDX
The strongest argument for BDX centers on Market Cap, Price/Book. PEG of 1.11 suggests the stock is reasonably priced for its growth.
Bull Case : NEPH
The strongest argument for NEPH centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 36.2% demonstrates continued momentum.
Bear Case : BDX
The primary concerns for BDX are Return on Equity, Profit Margin, P/E Ratio. A P/E of 44.6x leaves little room for execution misses. Thin 4.2% margins leave little buffer for downturns.
Bear Case : NEPH
The primary concerns for NEPH are Market Cap, Return on Equity, Piotroski F-Score.
Key Dynamics to Monitor
BDX profiles as a value stock while NEPH is a hypergrowth play — different risk/reward profiles.
NEPH carries more volatility with a beta of 1.64 — expect wider price swings.
NEPH is growing revenue faster at 36.2% — sustainability is the question.
BDX generates stronger free cash flow (509M), providing more financial flexibility.
Bottom Line
NEPH scores higher overall (59/100 vs 52/100) and 36.2% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Becton Dickinson and Company
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.
Visit Website →Nephros Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Nephros, Inc., a commercial stage company, develops and sells water solutions to the medical and commercial markets in the United States. The company is headquartered in South Orange, New Jersey.
Compare with Other MEDICAL INSTRUMENTS & SUPPLIES Stocks
Want to dig deeper into these stocks?